HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,953,654 | +5.1% | 77,321 | -0.7% | 0.00% | 0.0% |
| Q2 2023 | $2,809,990 | -31.2% | 77,904 | -27.2% | 0.00% | -50.0% |
| Q1 2023 | $4,085,444 | -31.2% | 106,977 | +2.5% | 0.00% | -20.0% |
| Q4 2022 | $5,940,360 | +100.7% | 104,400 | +39.5% | 0.01% | +66.7% |
| Q3 2022 | $2,960,000 | +61.3% | 74,854 | +79.5% | 0.00% | +50.0% |
| Q2 2022 | $1,835,000 | +37.8% | 41,705 | +24.9% | 0.00% | +100.0% |
| Q1 2022 | $1,332,000 | -35.3% | 33,401 | -34.8% | 0.00% | -50.0% |
| Q4 2021 | $2,059,000 | +44.0% | 51,194 | +45.7% | 0.00% | +100.0% |
| Q3 2021 | $1,430,000 | -12.1% | 35,145 | -1.8% | 0.00% | 0.0% |
| Q2 2021 | $1,626,000 | +29.2% | 35,807 | +18.5% | 0.00% | 0.0% |
| Q1 2021 | $1,259,000 | -38.8% | 30,210 | -37.3% | 0.00% | -50.0% |
| Q4 2020 | $2,056,000 | +156.0% | 48,150 | +57.5% | 0.00% | +100.0% |
| Q3 2020 | $803,000 | +32.3% | 30,565 | +35.0% | 0.00% | 0.0% |
| Q2 2020 | $607,000 | +53.3% | 22,643 | +2.9% | 0.00% | 0.0% |
| Q1 2020 | $396,000 | -6.2% | 21,998 | -7.6% | 0.00% | 0.0% |
| Q4 2019 | $422,000 | +14.7% | 23,813 | +0.4% | 0.00% | 0.0% |
| Q3 2019 | $368,000 | +35.3% | 23,729 | +58.3% | 0.00% | – |
| Q3 2018 | $272,000 | +22.5% | 14,988 | +14.0% | 0.00% | – |
| Q2 2018 | $222,000 | +2.8% | 13,151 | +23.1% | 0.00% | – |
| Q4 2017 | $216,000 | +52.1% | 10,685 | -9.2% | 0.00% | – |
| Q3 2016 | $142,000 | +40.6% | 11,770 | +0.9% | 0.00% | – |
| Q2 2016 | $101,000 | -10.6% | 11,670 | -2.5% | 0.00% | – |
| Q1 2016 | $113,000 | -45.4% | 11,970 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $207,000 | -7.2% | 11,970 | -27.8% | 0.00% | 0.0% |
| Q3 2015 | $223,000 | -39.1% | 16,570 | +2.3% | 0.00% | 0.0% |
| Q2 2015 | $366,000 | -15.3% | 16,200 | -46.4% | 0.00% | -50.0% |
| Q1 2015 | $432,000 | +63.6% | 30,250 | +10.4% | 0.00% | +100.0% |
| Q4 2014 | $264,000 | +22.2% | 27,400 | +15.6% | 0.00% | 0.0% |
| Q3 2014 | $216,000 | -1.4% | 23,700 | +6.8% | 0.00% | 0.0% |
| Q2 2014 | $219,000 | +5.3% | 22,200 | +35.4% | 0.00% | 0.0% |
| Q1 2014 | $208,000 | -13.3% | 16,400 | +2.5% | 0.00% | -50.0% |
| Q4 2013 | $240,000 | – | 16,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |